Cited 5 times in
Survival Estimates after Stopping Sorafenib in Patients with Hepatocellular Carcinoma: NEXT Score Development and Validation
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김도영 | - |
dc.contributor.author | 김범경 | - |
dc.contributor.author | 김승업 | - |
dc.contributor.author | 박준용 | - |
dc.contributor.author | 안상훈 | - |
dc.contributor.author | 이혜원 | - |
dc.contributor.author | 전미영 | - |
dc.contributor.author | 한광협 | - |
dc.date.accessioned | 2018-07-20T11:58:44Z | - |
dc.date.available | 2018-07-20T11:58:44Z | - |
dc.date.issued | 2017 | - |
dc.identifier.issn | 1976-2283 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/161574 | - |
dc.description.abstract | Background/Aims: Limited information is available regarding patient survival after sorafenib discontinuation in patients with hepatocellular carcinoma (HCC). Thus, we developed and validated a novel survival prediction model. Methods: Clinical data from 409 patients with HCC who stopped taking sorafenib between September 2008 and February 2015 were reviewed. Results: In the training cohort, four factors were independent negative predictors of survival (p<0.05). Based on the β regression coefficient of each factor, we established the NEXT score (Survival after Stopping Nexavar Treatment), allocating 1 point each for an Eastern Cooperative Oncology Group score ≥2, Child-Pugh class B or C, serum sodium ≤135 mEq/L, and α-fetoprotein 〉400 ng/mL. Area under the receiver operating characteristic curve values to predict 1-, 3-, and 6-month survival rates were 0.805, 0.809, and 0.774, respectively, in the training cohort and 0.783, 0.728, and 0.673, respectively, in the validation cohort (n=137). When the training and validation cohorts were stratified into three risk groups (NEXT score 0 [low-risk] vs 1 to 2 [intermediate-risk] vs 3 to 4 [high-risk]), survival differed significantly between the groups (p<0.05, log-rank test). Conclusions: In patients with HCC, survival after stopping sorafenib is poor. However, risk estimates based on a new "NEXT score" may help predict survival and prognosis even in patients who discontinue sorafenib treatment. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Editorial Office of Gut and Liver | - |
dc.relation.isPartOf | GUT AND LIVER | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antineoplastic Agents* | - |
dc.subject.MESH | Area Under Curve | - |
dc.subject.MESH | Carcinoma, Hepatocellular/drug therapy | - |
dc.subject.MESH | Carcinoma, Hepatocellular/mortality* | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Liver Neoplasms/drug therapy | - |
dc.subject.MESH | Liver Neoplasms/mortality* | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Niacinamide/analogs & derivatives* | - |
dc.subject.MESH | Phenylurea Compounds* | - |
dc.subject.MESH | ROC Curve | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Risk Factors | - |
dc.subject.MESH | Severity of Illness Index* | - |
dc.subject.MESH | Survival Rate | - |
dc.subject.MESH | Withholding Treatment/statistics & numerical data* | - |
dc.title | Survival Estimates after Stopping Sorafenib in Patients with Hepatocellular Carcinoma: NEXT Score Development and Validation | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Internal Medicine | - |
dc.contributor.googleauthor | Hye Won Lee | - |
dc.contributor.googleauthor | Hyun Soo Kim | - |
dc.contributor.googleauthor | Seung Up Kim | - |
dc.contributor.googleauthor | Do Young Kim | - |
dc.contributor.googleauthor | Beom Kyung Kim | - |
dc.contributor.googleauthor | Jun Yong Park | - |
dc.contributor.googleauthor | Sang Hoon Ahn | - |
dc.contributor.googleauthor | Mi Young Jeon | - |
dc.contributor.googleauthor | Ja Yoon Heo | - |
dc.contributor.googleauthor | Soo Young Park | - |
dc.contributor.googleauthor | Yu Rim Lee | - |
dc.contributor.googleauthor | Sun Kyung Jang | - |
dc.contributor.googleauthor | Su Hyun Lee | - |
dc.contributor.googleauthor | Se Young Jang | - |
dc.contributor.googleauthor | Won Young Tak | - |
dc.contributor.googleauthor | Kwang-Hyub Han | - |
dc.identifier.doi | 10.5009/gnl16391 | - |
dc.contributor.localId | A00385 | - |
dc.contributor.localId | A00487 | - |
dc.contributor.localId | A00654 | - |
dc.contributor.localId | A01675 | - |
dc.contributor.localId | A02226 | - |
dc.contributor.localId | A03318 | - |
dc.contributor.localId | A05405 | - |
dc.contributor.localId | A04268 | - |
dc.relation.journalcode | J00954 | - |
dc.identifier.eissn | 2005-1212 | - |
dc.identifier.pmid | 28651299 | - |
dc.subject.keyword | Hepatocellular carcinoma | - |
dc.subject.keyword | Prediction | - |
dc.subject.keyword | Risk | - |
dc.subject.keyword | Sorafenib | - |
dc.subject.keyword | Survival | - |
dc.contributor.alternativeName | Kim, Do Young | - |
dc.contributor.alternativeName | Kim, Beom Kyung | - |
dc.contributor.alternativeName | Kim, Seung Up | - |
dc.contributor.alternativeName | Park, Jun Yong | - |
dc.contributor.alternativeName | Ahn, Sang Hoon | - |
dc.contributor.alternativeName | Lee, Hye Won | - |
dc.contributor.alternativeName | Jeon, Mi Young | - |
dc.contributor.alternativeName | Han, Kwang Hyup | - |
dc.contributor.affiliatedAuthor | Kim, Do Young | - |
dc.contributor.affiliatedAuthor | Kim, Beom Kyung | - |
dc.contributor.affiliatedAuthor | Kim, Seung Up | - |
dc.contributor.affiliatedAuthor | Park, Jun Yong | - |
dc.contributor.affiliatedAuthor | Ahn, Sang Hoon | - |
dc.contributor.affiliatedAuthor | Lee, Hye Won | - |
dc.contributor.affiliatedAuthor | Jeon, Mi Young | - |
dc.contributor.affiliatedAuthor | Han, Kwang Hyup | - |
dc.citation.volume | 11 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 693 | - |
dc.citation.endPage | 701 | - |
dc.identifier.bibliographicCitation | GUT AND LIVER, Vol.11(5) : 693-701, 2017 | - |
dc.identifier.rimsid | 61602 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.